| Bashir A Azher, MD | |
|
1467 Palma Rd, Suite 4, Bullhead City, AZ 86442-6785 | |
| (928) 763-5110 | |
| (928) 763-1091 |
| Full Name | Bashir A Azher |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 54 Years |
| Location | 1467 Palma Rd, Bullhead City, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689605404 | NPI | - | NPPES |
| AZ0181640 | Other | AZ | BLUE CROSS |
| 239542002 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 14725 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Western Arizona Regional Medical Center | Bullhead city, AZ | Hospital |
| Kingman Regional Medical Center | Kingman, AZ | Hospital |
| Valley View Medical Center | Fort mohave, AZ | Hospital |
| Havasu Regional Medical Center | Lake havasu city, AZ | Hospital |
| Entity Name | Bashir Ahmed Azher Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760671804 PECOS PAC ID: 8729261128 Enrollment ID: O20110322001037 |
News Archive
Currently no treatment option is available for five percent of patients suffering from chronic myelogenous leukemia, since they have developed resistance to conventional medications. Prof. Stephan Grzesiek's group at the Biozentrum of the University of Basel, in collaboration with Dr. Wolfgang Jahnke and colleagues from Novartis, has investigated the combined action of two different compounds against this form of leukemia.
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company's potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).
Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced it has completed the acquisition of an active pharmaceutical ingredient (API) manufacturing facility and an associated research and development (R&D) facility from Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $218 million, after settling prior advances of approximately $30 million.
The cells and tissues in our bodies grow, develop and interact in a highly complex, three-dimensional world. Likewise, the various microbial pathogens that invade our bodies and cause infectious disease interact with this complex 3-D tissue milieu. In the current issue of the journal Nature Reviews Microbiology, researcher Cheryl Nickerson and her team at the Biodesign Institute at Arizona State University highlight an innovative approach for studying cells in 3-D.
It is well known that psychiatric stress is associated with accelerated aging. Now, a new study shows that a gene mutation interacts with multiple types of psychiatric stress including post-traumatic stress disorder (PTSD), pain and sleep disturbances in association with cellular aging.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bashir A Azher, MD 1467 Palma Rd, Suite 4, Bullhead City, AZ 86442-6785 Ph: (928) 763-5110 | Bashir A Azher, MD 1467 Palma Rd, Suite 4, Bullhead City, AZ 86442-6785 Ph: (928) 763-5110 |
News Archive
Currently no treatment option is available for five percent of patients suffering from chronic myelogenous leukemia, since they have developed resistance to conventional medications. Prof. Stephan Grzesiek's group at the Biozentrum of the University of Basel, in collaboration with Dr. Wolfgang Jahnke and colleagues from Novartis, has investigated the combined action of two different compounds against this form of leukemia.
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company's potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).
Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced it has completed the acquisition of an active pharmaceutical ingredient (API) manufacturing facility and an associated research and development (R&D) facility from Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $218 million, after settling prior advances of approximately $30 million.
The cells and tissues in our bodies grow, develop and interact in a highly complex, three-dimensional world. Likewise, the various microbial pathogens that invade our bodies and cause infectious disease interact with this complex 3-D tissue milieu. In the current issue of the journal Nature Reviews Microbiology, researcher Cheryl Nickerson and her team at the Biodesign Institute at Arizona State University highlight an innovative approach for studying cells in 3-D.
It is well known that psychiatric stress is associated with accelerated aging. Now, a new study shows that a gene mutation interacts with multiple types of psychiatric stress including post-traumatic stress disorder (PTSD), pain and sleep disturbances in association with cellular aging.
› Verified 7 days ago